Bridging the Gap between Genomics and Clinical Outcomes in CHD
缩小先心病基因组学与临床结果之间的差距
基本信息
- 批准号:9123653
- 负责人:
- 金额:$ 40.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-15 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAllelesBioinformaticsCandidate Disease GeneCardiac MyocytesCardiovascular systemChildhoodClinicalClinical DataCodeCollectionComputer softwareCopy Number PolymorphismDNADataData SetDatabasesDevelopmentDiagnosisDiagnosticDiseaseDisease modelEnrollmentExhibitsFamilyFoundationsGenesGenomeGenomicsGenotypeGoalsHealthHeartHeritabilityHeterozygoteInstitutional Review BoardsInvestigationKnowledgeLinkMedical RecordsMethodologyMiningMulticenter StudiesNational Heart, Lung, and Blood InstituteNucleotidesOutcomeParentsParticipantPatientsPediatric Cardiac Genomics ConsortiumPediatric cardiologyPenetrancePhenotypePlayPopulation DatabasePublishingQualifyingRNA SplicingReportingResearchResearch InfrastructureResearch PersonnelResourcesRoleSamplingScientistSiteSolidSurfaceTechnologyTranscendUniversitiesUntranslated RNAUtahVariantWorkabstractingbasecongenital heart disorderdesignempoweredexome sequencinggene discoverygenetic pedigreegenetic variantgenome sequencinggenomic datagenotyped patientsinduced pluripotent stem cellinnovationknowledge baseneurodevelopmentnoveloutcome forecastoutcome predictionpredict clinical outcomeprobandsegregationsuccesstoolwhole genome
项目摘要
DESCRIPTION (provided by applicant): Despite the allocation of significant resources, the genomic basis of congenital heart disease (CHD) remains largely unknown in that rare and de novo single nucleotide and copy-number variants account for a small fraction of CHD. We hypothesize that (1) rare incompletely dominant, simple recessive, and compound- heterozygote disease models account for a very significant fraction of the "missing heritability" o CHD and (2) the genomic load of deleterious variants, together with pleomorphies associated with some CHD-causing alleles (but not others), influence clinical outcomes in a manner that transcends their immediate contribution to the primary CHD. Our principal goal is to establish the Utah Center as an integral partner of the Pediatric Cardiac Genomics Consortium (PCGC) and to work collaboratively with other PCGC centers in order to (1) provide the PCGC with the patients, expertise and software that will identify the missing heritability of CHD; and (2) associate genomic variants with relevant clinical outcomes by defining the pleomorphies associated with CHD-causing alleles and by determining the genomic load of deleterious variants. Currently, the PCGC is lacking two key diagnostic approaches that hinder its ability to define the genomic basis for CHD and its outcomes: (1) a robust bioinformatics pipeline that is capable of computing on incompletely dominant, simple recessive, and compound-heterozygote disease models, and (2) a family-based whole-genome sequencing approach that is powered to identify novel CHD alleles in coding and non-coding regions. We argue that the identification of de novo variants in PCGC proband-parent trios represents only the tip of the iceberg, with many genes and alleles still undiscovered. This proposal encompasses innovative methodologies that will benefit the PCGC in a very practical manner. This proposal capitalizes on a recently validated and emerging bioinformatics technology that provides four basic functionalities: (1) the ability to estimate the functional impact of variants no matter where they lie in the genome coding, intergenic, splice sites, etc.; (2) the ability to computationally interrogate patient genotypes not only for dominant de novo alleles, but also for incompletely penetrant dominant, simple recessive, and compound heterozygote disease models; (3) the ability to carry out these analyses in the context of pedigrees, phenotype information, and expression data from patient-specific induced pluripotent stem cell-derived cardiomyocytes; and (4) the capability to share results for patient management and consortium-wide collaborative analyses. In summary, our proposal aims to fill the knowledge gap of "missing heritability" surrounding CHD by leveraging novel tools designed at the University of Utah that enable integrated computation on personal genome/exome sequences, patient phenotype descriptions and pedigrees, and patient-specific expression data, all in a robust statistical framework.
描述(申请人提供):尽管分配了大量的资源,先天性心脏病(CHD)的基因组基础仍然很大程度上是未知的,因为罕见的从头开始的单核苷酸和拷贝数变异只占CHD的一小部分。我们假设(1)罕见的不完全显性、简单隐性和复合杂合子疾病模型在CHD的“缺失遗传性”中占非常重要的比例,(2)有害变异的基因组负荷,以及与一些导致CHD的等位基因(但不是其他)相关的多态,以一种超越其对原发CHD的直接贡献的方式影响临床结果。我们的主要目标是将犹他州中心建立为儿科心脏基因组联盟(PCGC)不可或缺的合作伙伴,并与其他PCGC中心合作,以便(1)向PCGC提供患者、专业知识和软件,以确定CHD缺失的遗传性;以及(2)通过定义与导致CHD的等位基因相关的多态和确定有害变量的基因组负载,将基因组变体与相关临床结果联系起来。目前,PCGC缺乏两种关键的诊断方法,这两种方法阻碍了其定义CHD及其结果的基因组基础的能力:(1)能够计算不完全显性、简单隐性和复合杂合子疾病模型的强大的生物信息学管道;(2)能够在编码区和非编码区识别新的CHD等位基因的基于家族的全基因组测序方法。我们认为,在PCGC先证者-亲代三人组中识别从头变异只是冰山一角,许多基因和等位基因仍未被发现。这项建议包含了创新的方法,这些方法将以非常实际的方式使PCGC受益。这一建议利用了一种最近得到验证的新兴生物信息学技术,该技术提供了四种基本功能:(1)无论变异位于基因组编码、基因间、剪接位点等什么位置,都能够估计它们的功能影响;(2)不仅能够计算询问患者的新等位基因,而且还能够对不完全穿透性显性、简单隐性和复合杂合子疾病模型进行计算;(3)能够在患者特定诱导的多能干细胞来源的心肌细胞的家系、表型信息和表达数据的背景下进行这些分析;以及(4)共享患者管理和联盟范围内协作分析的结果的能力。总之,我们的建议旨在通过利用犹他大学设计的新工具来填补围绕CHD的“缺失遗传性”的知识空白,这些工具能够在一个强大的统计框架中对个人基因组/外显子组序列、患者表型描述和系谱以及患者特定的表达数据进行集成计算。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARTIN TRISTANI-FIROUZI其他文献
MARTIN TRISTANI-FIROUZI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARTIN TRISTANI-FIROUZI', 18)}}的其他基金
A Novel Role for NFATC1 in Modulating Cardiac Excitability
NFATC1 在调节心脏兴奋性中的新作用
- 批准号:
10026527 - 财政年份:2020
- 资助金额:
$ 40.08万 - 项目类别:
A Novel Role for NFATC1 in Modulating Cardiac Excitability
NFATC1 在调节心脏兴奋性中的新作用
- 批准号:
10653775 - 财政年份:2020
- 资助金额:
$ 40.08万 - 项目类别:
A Novel Role for NFATC1 in Modulating Cardiac Excitability
NFATC1 在调节心脏兴奋性中的新作用
- 批准号:
10449135 - 财政年份:2020
- 资助金额:
$ 40.08万 - 项目类别:
Integrating Genomic and Clinical Approaches to Sudden Death in the Young
结合基因组学和临床方法治疗年轻人猝死
- 批准号:
9242064 - 财政年份:2016
- 资助金额:
$ 40.08万 - 项目类别:
Bridging the Gap between Genomics and Clinical Outcomes in CHD
缩小先心病基因组学与临床结果之间的差距
- 批准号:
8950472 - 财政年份:2015
- 资助金额:
$ 40.08万 - 项目类别:
Bridging the Gap between Genomics and Clinical Outcomes in CHD
缩小先心病基因组学与临床结果之间的差距
- 批准号:
10237337 - 财政年份:2015
- 资助金额:
$ 40.08万 - 项目类别:
Bridging the Gap between Genomics and Clinical Outcomes in CHD
缩小先心病基因组学与临床结果之间的差距
- 批准号:
9324036 - 财政年份:2015
- 资助金额:
$ 40.08万 - 项目类别:
Bridging the Gap between Genomics and Clinical Outcomes in CHD
缩小先心病基因组学与临床结果之间的差距
- 批准号:
10477466 - 财政年份:2015
- 资助金额:
$ 40.08万 - 项目类别:
Bridging the Gap between Genomics and Clinical Outcomes in CHD
缩小先心病基因组学与临床结果之间的差距
- 批准号:
10027913 - 财政年份:2015
- 资助金额:
$ 40.08万 - 项目类别:
Voltage Sensor Movement in the HERG Potassium Channel
HEG 钾通道中的电压传感器移动
- 批准号:
7340392 - 财政年份:2004
- 资助金额:
$ 40.08万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 40.08万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 40.08万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 40.08万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 40.08万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 40.08万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 40.08万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 40.08万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 40.08万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 40.08万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 40.08万 - 项目类别: